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Abstract
Background/Aims: We investigated the effect of the per-
oxisome proliferator-activated receptor-Á (PPAR-Á) ago-
nist pioglitazone on growth and TRAIL-induced apopto-
sis in carcinoid cells. Methods: Carcinoid cells were incu-
bated without and with pioglitazone. Effects on growth
were examined by cell count and cell cycle analysis.
p21waf1/cip1 expression was determined by Western blot-
ting. Cytotoxicity assay was performed by FACS analy-
sis. Results: Pioglitazone suppressed the growth and
induced apoptosis of carcinoid cells. Additionally, piogli-
tazone significantly enhanced carcinoid cell death in-
duced by tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL). The enhancement of TRAIL-
induced apoptosis was associated with an upregulation
of cyclin-dependent kinase inhibitor p21waf1/cip1 in piogli-
tazone-treated carcinoid cells. Importantly, overexpres-
sion of p21waf1/cip1 in carcinoid cells by adenoviral gene
transfer of p21 sensitized them to TRAIL-induced apopto-
sis. Conclusions: These results suggest that pioglitazone
inhibits cell growth and sensitizes cells to TRAIL-induced
apoptosis by induction of p21waf1/cip1. Therefore, pioglita-
zone can be an effective therapeutic adjuvant for the
treatment of carcinoid tumors.
Copyright © 2001 S. Karger AG, Basel
Introduction
Tumor necrosis factor (TNF)-related apoptosis-induc-
ing ligand (TRAIL) is a newly identified member of the
TNF family [1]. It shares the highest sequence homology
with Fas (CD95, Apo-1) ligand, another member of the
TNF family that is capable of inducing apoptosis. How-
ever, in contrast to Fas ligand (FasL), TRAIL induces
apoptosis of a variety of tumor cells, but not normal cells
[2]. To date, five different receptors for TRAIL have been
identified: i.e. Death Receptor 4 (DR4, TRAIL-R1),
Death Receptor 5 (DR5, TRAIL-R2), Decoy Receptor 1
(DcR1, TRAIL-R3, TRID), Decoy Receptor 2 (DcR2,
TRAIL-R4, TRUNDD), and osteoprotegerin. Binding of
TRAIL to either DR4 or DR5 recruits FADD to its intra-
cellular death domain and activates the caspase cascade
resulting in cell death [3, 4]. DcR1 and DcR2 are decoy
receptors that do not transduce apoptotic signals but may
protect cells from TRAIL-induced apoptosis [5–8]. Osteo-
protegerin is the only known soluble receptor for TRAIL,
which has been reported to regulate osteoclastogene-
sis [9].
Pioglitazone is an antidiabetic thiazolidinedione that
specifically activates the nuclear transcription factor
PPAR-Á. PPAR-Á exists in two isoforms, PPAR-Á1 and
PPAR-Á2 [10]. While PPAR-Á2 is expressed primarily in
adipocytes, PPAR-Á1 has been identified in a variety of
tissues [10, 11]. It has been reported that PPAR-Á plays
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important roles in lipid metabolism and inflammation
[10] and that activation of PPAR-Á induces apoptosis of
differentiated macrophages and macrophages activated
by TNF-· or interferon-Á [12]. We have recently reported
that PPAR-Á regulates TRAIL-induced apoptosis of Jur-
kat T cells and colon cancer cells (HT-29 and SW480)
[13]. In this report, we studied the effect of pioglitazone
on the growth and apoptosis of carcinoid cells, and dis-
covered a novel role for cyclin-dependent kinase inhibitor
p21waf1/cip1 in TRAIL-induced apoptosis. Treatment of
endocrine tumors is extremely challenging because they
are resistant to chemotherapy and radiation and show
only a limited sensitivity to hormones and cytokines such
as somatostatin or interferon-· [14]. Data reported here
suggest that a combination of TRAIL and pioglitazone
may be effective in treating these tumors.
Materials and Methods
Cell Lines and Reagents
NCI-H727 carcinoid cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 1% penicillin/strep-
tomycin. Pioglitazone (Takeda, Osaka, Japan) was dissolved in
dimethyl sulfoxide (DMSO) and added to the cell culture to a final
concentration of 20 ÌM. Control cultures received the same amount
of DMSO (which was less than 0.2% of the medium).
RT-PCR
Total RNA was extracted from cells using the RNeasy kit, and
reverse transcribed to cDNA using the Omniscript cDNA synthesis
kit with hexamer primers (Quiagen, Valencia, Calif., USA) per man-
ufacturer’s instructions. For detection of PPAR-Á mRNA, the follow-
ing primers were used: Sense primer, 5)-TCTCTCCGTAATGGAA-
GACC-3), and antisense primer, 5)-GCATTATGAGACATCCC-
CAC-3) [15]. PCR amplification was performed using Taq poly-
merase (Promega, Madison, Wisc., USA) under the following condi-
tions: Denaturation at 95°C for 2 min, amplification for 35 cycles
(95°C for 45 s, 55°C for 1 min and 72°C for 1 min), and extension at
72°C for 7 min. The PCR products were then separated by electro-
phoresis on a 1% (w/v) agarose gel containing ethidium bromide.
Cell Cycle Analysis
Cells were cultured in 75 cm2 cell culture flasks with or without
20 ÌM pioglitazone for 4 days. Cells were then harvested, and fixed
in ice-cold 70% (v/v) ethanol for 24 h at 4°C. After centrifugation
(2,000 g, 4 °C, 4 min), the cell pellet was resuspended in phosphate-
buffered saline (PBS) (pH 7.4) containing 1 Ìg/ml of DNase-free
RNase, 50 Ìg/ml of propidium iodide (PI) and 0.1% glucose. Cells
were incubated at room temperature in the dark for 4 h, and DNA
content was determined by flow cytometry using a FACScan flow
cytometer (Becton-Dickinson, San Jose, Calif., USA). Histograms
were analyzed using the ModFit 2.0 software (Verity Software
House, Topsham, Me., USA).
Fig. 1. PPAR-Á expression in NCI-H727
carcinoid cells and HT-29 colon cancer cells.
Total RNA was extracted and RT-PCR
was performed as described in ‘Methods’.
PPAR-Á expression (474 bp) in NCI-H727
and HT-29 cells is shown in lanes 1 and 2,
respectively.
Cytotoxicity Assay
Cells were pre-incubated in 24-well plates with or without piogli-
tazone for various times followed by an incubation with or without
recombinant human TRAIL (Biomol, Plymouth Meeting, Pa., USA)
for 16 h at 37°C. Cells were then harvested, washed and resuspended
in PBS (pH 7.4) containing 1 mM glucose and 2 Ìg/ml of propidium
iodide. PI fluorescence intensity was determined by flow cytometry
using a FACScan flow cytometer.
Western Blot Analysis
Cell lysates were first separated by polyacrylamide gel electropho-
resis. The p21waf1/cip1 protein was then detected by Western blotting
[16] using an anti-p21waf1/cip1 antibody (clone SXM30) from Phar-
mingen (San Diego, Calif., USA).
Results
Pioglitazone Inhibits Growth of Carcinoid Cells by
Blocking Cell Cycle Progression
PPAR-Á is constitutively expressed in a variety of cell
types [17, 18]. To determine whether PPAR-Á is ex-
pressed in carcinoid cells, we tested its gene expression in
NCI-H727 cells by PCR. As shown in figure 1, PPAR-Á
mRNA is readily detectable in NCI-H727 cells as well as
HT-29 colon cancer cells which are known to express high
levels of PPAR-Á mRNA [19].
To determine the effect of PPAR-Á activation on the
growth of NCI-H727 carcinoid cells, we treated them with
20 ÌM pioglitazone for up to 8 days. As shown in fig-
ure 2a, treatment with pioglitazone significantly inhibited
the proliferation of carcinoid cells. This was associated
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Fig. 2. a Pioglitazone inhibits growth of NCI-H727 carcinoid cells. 1.25 ! 104 cells were cultured with or without 20
ÌM pioglitazone for up to 8 days. The number of cells in each culture was determined using a Rosenthal counting
chamber. Data presented are means of duplicated cultures of a representative experiment. b Pioglitazone inhibits cell
growth and prevents colonization of NCI-H727 cells. NCI-H727 cells were cultured with or without 20 ÌM pioglita-
zone for 4 days, stained with hematoxylin/eosin, and examined by light microscopy. Original magnification !200.
Fig. 3. Effect of pioglitazone on cell cycle progression in NCI-H727
cells. NCI-H727 cells, 106 cells/ml, were cultured with or without
20 ÌM pioglitazone for 4 days. Cells were then harvested, fixed in
70% ethanol, and stained with propidium iodide. The percentage of
cells in each phases of cell cycle was determined by flow cytometry
using the ModFit 2.0 software.
with a reduced ability of these cells to colonize (fig. 2b).
Further analysis of these cells revealed significant block-
ade of cell cycle progression by pioglitazone (fig. 3). Spe-
cifically, pioglitazone increased the percentage of cells in
the G0/G1 phase while it decreased the percentage of cells
in the S phase of the cell cycle (fig. 3).
Pioglitazone Enhances TRAIL-Induced Apoptosis of
Carcinoid Cells
To determine whether PPAR-Á plays any role in
TRAIL-induced apoptosis of carcinoid cells, we pre-
treated NCI-H727 cells with 20 ÌM pioglitazone for 4
days and then examined their sensitivity to TRAIL-
induced apoptosis. As shown in figure 4, TRAIL alone
induced moderate apoptosis of these cells, suggesting that
they are sensitive to TRAIL-induced apoptosis. Pretreat-
ment of these cells with pioglitazone significantly in-
creased their sensitivity to TRAIL-induced apoptosis,
with the percentage of apoptotic cells increased by 3-fold
in the pioglitozone-treated group (fig. 4). Pioglitozone
alone also induced detectable apoptosis of carcinoid cells,
which is consistent with reports of the effect of PPAR-Á
agonists on other cell types [15, 20].
3
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Fig. 4. Pioglitazone enhances TRAIL-induced apoptosis of NCI-
H727 cells. NCI-H727 cells, 5 ! 105 cells/ml, were cultured with or
without 20 ÌM pioglitazone for 4 days. Cells were then treated with
200 ng/ml of TRAIL for 16 h. The percentage of apoptotic cells was
determined by flow cytometry as described in Methods. Data pre-
sented are means B SEM of the percentages of apoptotic cells pooled
from two experiments. Control cells were treated with vehicle alone.
Pio = Pioglitazone.
Fig. 5. Pioglitazone induces p21waf1/cip1 expression in NCI-H727
cells. NCI-H727 cells, 106 cells/ml, were cultured with 20 ÌM piogli-
tazone for 4 days. Proteins were extracted and p21waf1/cip1 protein was
detected by Western blot analysis. Each lane was loaded with 50 Ìg
protein. Lane 1 = Cells treated with vehicle; lane 2 = cells treated with
pioglitazone.
Fig. 6. Expression of p21waf1/cip1 in NCI-H727 cells infected with
Adp21waf1/cip1. NCI-H727 cells, 106 cells/ml, were infected with
2.5 ! 109 particles of Adp21waf1/cip1 (lane 3). Control cells were either
noninfected (lane 1) or infected with 2.5 ! 109 particles of AdLacZ
(lane 2). Proteins were extracted and p21waf1/cip1 was detected by
Western blot analysis. Each lane was loaded with 50 Ìg protein.
Fig. 7. Overexpression of p21waf1/cip1 enhances TRAIL-induced
apoptosis. NCI-H727 cells, 106 cells/ml, were either infected or not
infected with 2.5 ! 109 particles of Adp21waf1/cip1. 24 h later, cells
were cultured with or without TRAIL (1 Ìg/ml) for an additional
16 h. The percentage of apoptotic cells was determined by flow
cytometry as described in ‘Methods’. Data presented are means B
SEM of percentages of apoptotic cells pooled from two experiments.
** p ! 0.005 as determined by ANOVA.
p21waf1/cip1 Expression Promotes TRAIL-Induced
Apoptosis in Carcinoid Cells
Recently, it was reported that the PPAR-Á agonist tro-
glitazone upregulates the cyclin-dependent kinase inhibi-
tor p21waf1/cip1 in several tumor cell lines [21]. However,
the role of p21waf1/cip1 in apoptosis is unclear. Several
reports suggest that p21waf1/cip1 may prevent cell death
[22–24]. On the other hand, Fas (CD95) ligation in T cells
induces expression of p21waf1/cip1 and promotes Fas-
induced apoptosis [25].
To explore the potential roles of p21waf1/cip1 in TRAIL-
induced apoptosis and its regulation by PPAR-Á, we
examined the effect of PPRA-Á on p21waf1/cip1 expression
and its impact on TRAIL-induced apoptosis. As shown in
figure 5, p21waf1/cip1 expression was significantly increased
in carcinoid cells treated with 20 ÌM pioglitazone. This
may explain the cell cycle arrest induced by pioglitazone
as shown in figure 3. To directly examine the effect of
upregulated p21waf1/cip1 expression on TRAIL-induced
apoptosis, we infected carcinoid cells with a recombinant
adenovirus carrying the p21waf1/cip1 gene. As shown in fig-
ure 6, expression of p21waf1/cip1 was dramatically increased
in cells infected with p21waf1/cip1 virus, but not the control
virus. Since the exposure time of the film was only 10 s,
basal expression of p21 was not detectable in controls.
Figure 5 shows that basal p21 expression in controls
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is detectable after an exposure time of 1 min. Importantly,
overexpression of p21waf1/cip1 significantly increased the
sensitivity of these cells to TRAIL-induced apoptosis
(fig. 7).
Discussion
TRAIL is a newly described member of the TNF
superfamily, which shares the highest homology with
FasL. However, unlike FasL, TRAIL selectively kills
transformed tumor cells, but not most nontransformed
normal cells. Putative mechanisms responsible for the
TRAIL resistance include the expression of TRAIL decoy
receptors on the cell surface and/or expression of anti-
apoptotic genes such as FLIP, IAP or survivin in resistant
cells [26–28]. Expression of anti-apoptotic or survival
genes may be regulated by transcription factors such as
NF-ÎB and PPAR-Á [29]. We have previously reported
that TRAIL-induced apoptosis in Jurkat cells and colon
cancer cells is regulated by these transcription factors.
Activation of the nuclear receptor PPAR-Á or inhibition
of NF-ÎB resulted in an increased sensitivity of cells to
TRAIL-induced apoptosis [13]. Encouraged by these re-
sults and other studies demonstrating a pro-apoptotic
effect of thiazolidinediones on tumor cells [15, 20], we
investigated the effect and the mechanisms of action of a
PPAR-Á agonist in TRAIL-induced apoptosis using a car-
cinoid cell line, NCI-H727. NCI-H727 cells were origi-
nally derived from a lung carcinoid tumor and are the
best-characterized carcinoid cells. We found that pioglita-
zone inhibits the growth of NCI-H727 cells by blocking
G1-to-S phase cell cycle progression and sensitizes them
to TRAIL-induced apoptosis. Furthermore, we demon-
strated that pioglitazone upregulates the expression of
cyclin-dependent kinase inhibitor p21waf1/cip1, which in
turn is capable of sensitizing carcinoid cells to TRAIL-
induced apoptosis. To our knowledge, this is the first
report on the role of p21waf1/cip1 in TRAIL-induced apop-
tosis.
Several reports suggest that thiazolidinediones alone
are capable of inducing apoptosis of tumor cell lines [15,
20]. Although the precise pro-apoptotic actions of these
substances remain to be elucidated, PPAR-Á-mediated
inhibition of NF-ÎB has been suggested to be involved
[13, 30]. Results reported here indicate that the cyclin-
dependent kinase inhibitor p21waf1/cip1 may also play an
important role in this process. p21waf1/cip1 is involved in
multiple biological functions including the inhibition
of cyclin-dependent kinases, which results in suppression
of cell cycle progression [31]. However, the roles of
p21waf1/cip1 in apoptosis are poorly understood. Previous
reports suggest that p21waf1/cip1 may play an anti-apoptotic
role by inhibiting cyclin-dependent kinases, or by regu-
lating the functions of caspases, stress-activated kinases,
or survival genes [32]. On the other hand, it has also
been shown that overexpression of p21waf1/cip1 promotes
apoptosis of BHK21 cells [33]. Our results suggest that
p21waf1/cip1 expression enhances TRAIL-induced apopto-
sis in carcinoid cells. This is consistent with a recent
report that p21waf1/cip1 promotes Fas-induced apoptosis in
T cells [25]. However, it is unclear whether the apoptotic
activity of p21waf1/cip1 is resulted from its effect on cell
cycle. In this regard, it has been reported that although the
transcription factor E2F regulates both cell cycle and
apoptosis [34, 35], the two functions are not mutually
dependent on each other [36]. Since p21waf1/cip1 has been
shown to directly interact with the transcription factor
E2F [37], it is conceivable that it may promote the apop-
totic effect of the E2F while inhibit its effect on cell cycle.
Treatment of neuroendocrine tumors remains ex-
tremely challenging. In the case of carcinoid tumors, sur-
gery is rarely curative and external radiation therapy has
not been successful [14]. Similarly, carcinoid tumors
respond poorly to chemotherapy with only a small frac-
tion of them responding to streptozotocin, doxorubicin or
5-fluorouracil [38, 39]. Somatostatin analogues inhibit the
release of peptide hormones from neuroendocrine tumors
attenuating clinical symptoms. However, tumor reduc-
tion is observed only in less than 10% of patients treated
with somatostatin analogues [40, 41]. Finally, although
50% of the patients with carcinoid tumors respond to
interferon-· therapy, only about 15% of them show signif-
icant tumor shrinkage [41]. Data reported here suggest
that pioglitazone inhibits growth of carcinoid cells and
sensitizes them to TRAIL-induced apoptosis. Thus, a
combination of pioglitazone and TRAIL may be an effec-
tive therapeutic regimen for the treatment of carcinoid
tumors.
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